142 related articles for article (PubMed ID: 31006846)
1. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation.
Neumann E; Klaiber P; Freitag K; Schwab M; Schaeffeler E; Hennenlotter J; Fend F; Kruck S; Scharpf M; Stenzl A; Bedke J; Rausch S
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1835-1843. PubMed ID: 31006846
[TBL] [Abstract][Full Text] [Related]
2. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy.
Viers BR; Houston Thompson R; Psutka SP; Lohse CM; Cheville JC; Leibovich BC; Tollefson MK; Boorjian SA
Urol Oncol; 2015 Sep; 33(9):388.e11-8. PubMed ID: 25700974
[TBL] [Abstract][Full Text] [Related]
3. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
4. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
5. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
[TBL] [Abstract][Full Text] [Related]
7. Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated renal cell carcinoma.
Berquist SW; Lee HJ; Hamilton Z; Bagrodia A; Hassan AE; Beksaç AT; Dufour CA; Wang S; Mehrazin R; Patterson A; Derweesh IH
Minerva Urol Nefrol; 2017 Oct; 69(5):501-508. PubMed ID: 28376607
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma.
Gayed BA; Youssef RF; Bagrodia A; Kapur P; Darwish OM; Krabbe LM; Sagalowsky A; Lotan Y; Margulis V
J Urol; 2013 Nov; 190(5):1662-7. PubMed ID: 23792148
[TBL] [Abstract][Full Text] [Related]
9. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma.
Pflanz S; Brookman-Amissah S; Roigas J; Kendel F; Hoschke B; May M
Scand J Urol Nephrol; 2008; 42(6):507-13. PubMed ID: 19031267
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project).
May M; Surcel C; Capitanio U; Dell'Oglio P; Klatte T; Shariat S; Ecke T; Wolff I; Vergho D; Wagener N; Huck N; Pahernik S; Zastrow S; Wirth M; Borgmann H; Haferkamp A; Musquera M; Krabbe LM; Herrmann E; Scavuzzo A; Mirvald C; Hutterer G; Zigeuner R; Stief CG; Waidelich R; Cindolo L; Kalusova K; Brookman-May SD;
Scand J Urol; 2017 Aug; 51(4):269-276. PubMed ID: 28399699
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
Ghavamian R; Cheville JC; Lohse CM; Weaver AL; Zincke H; Blute ML
J Urol; 2002 Aug; 168(2):454-9. PubMed ID: 12131287
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications.
Haferkamp A; Kurosch M; Pritsch M; Hatiboglu G; Macher-Goeppinger S; Pfitzenmaier J; Pahernik S; Wagener N; Hohenfellner M
Ann Surg Oncol; 2010 Feb; 17(2):544-51. PubMed ID: 19953334
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of renicapsular involvement in Stages I and II renal cell carcinoma from the morphological and prognostic point of view.
May M; Brookman-Amissah S; Roigas J; Gilfrich CP; Pflanz S; Hoschke B; Gunia S
Urol Oncol; 2010; 28(3):274-9. PubMed ID: 18805709
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
Van Poppel H; Da Pozzo L; Albrecht W; Matveev V; Bono A; Borkowski A; Colombel M; Klotz L; Skinner E; Keane T; Marreaud S; Collette S; Sylvester R
Eur Urol; 2011 Apr; 59(4):543-52. PubMed ID: 21186077
[TBL] [Abstract][Full Text] [Related]
18. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.
Tsui KH; Shvarts O; Smith RB; Figlin RA; deKernion JB; Belldegrun A
J Urol; 2000 Apr; 163(4):1090-5; quiz 1295. PubMed ID: 10737472
[TBL] [Abstract][Full Text] [Related]
19. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of clinical and pathological factors for surgically treated localized clear cell renal cell carcinoma.
Teng J; Gao Y; Chen M; Wang K; Cui X; Liu Y; Xu D
Chin Med J (Engl); 2014; 127(9):1640-4. PubMed ID: 24791867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
